BORISOV, Valeriy Alexandrovich;БОРИСОВ, Валерий Александрович;BORISOV; Valeriy Alexandrovich
发明人:
BORISOV, Valeriy Alexandrovich,БОРИСОВ, Валерий Александрович
申请号：
RURU2012/000510
公开号：
WO2013/015714A1
申请日:
2012.06.26
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
The invention relates to medicine, more specifically hepatology, and can be used for treating chronic viral hepatitis C, the causative agent of which can be of any genotype. The technical result of the proposed method is a reduction in the aggressiveness of antiviral therapy together with an increase in stable positive therapeutic results. In the claimed method for treating chronic viral hepatitis C, which involves administering short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil to the patient, an average weekly starting dose of interferons in a range of 10.5-21.0 million SU is determined on the basis of the patient's own interferon-alpha level, and interferon-alpha is administered with an at least twofold gradual increase in the average weekly dose of interferons to a value of 21.0-84 million SU. Throughout the entire IFN administration period, additional antiviral drugs, namely an interferon inducer, are administered to the patient, as well as an amantadine group preparation or a glycyrrhizic acid preparation. At the same time, a concomitant treatment is carried out which involves the administration of T cell immunity stimulators and preparations for combating side effects. The presence of viral ribonucleic acid (RNA) in the patient's blood is periodically monitored: a daily dose of 800-1200 mg of Ribamidil is administered starting from the third month from the commencement of treatment if ribonucleic acid (RNA) is present in the patient's blood, or starting from the tenth month if no RNA is present. Treatment is continued until at least a twelve month period of aviremia has passed.L'invention se rapporte au domaine de la médecine, plus particulièrement au domaine de l'hépatologie, et peut s'utiliser pour traiter l'hépatite C virale chronique présentant n'importe quel génotype de l'agent. Le résultat technique de ce procédé consiste à réduire l'agressivité de la thérapie antivirale tout en augmentant le résultat thérapeutique stable et positi
